Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis

Vivien Hsu1,3 · Mark Bramwit2 · Naomi Schlesinger1

Abstract We examined the usefulness of dual-energy computed tomography (DECT) in the evaluation of symptomatic systemic sclerosis (SSc)-related calcinosis of the hands. We performed DECT scan of the hands in 16 patients with symptomatic SSc-calcinosis to better characterize the calcinosis, their locations within the soft tissues, and exclude monosodium urate (MSU) crystal deposition. We also compared their computed tomography (CT) images to plain radiographs of one hand. Pertinent clinical information from this cohort was collected. Sixteen SSc patients underwent DECT and plain X-ray imaging of the hands. Five of the 16 SSc patients in our cohort had overlap disease, either rheumatoid arthritis (RA) and/or myopathy. Calcino sis symptoms included painful deposits (88 %), soft tissue swelling (66 %), and recurrent infections (44 %) from these deposits. On DECT, calcinosis deposits had the same color and density as the bone and no MSU was found. However, their CT images showed better details of the calcinosis locations in the soft tissues as well as the bone destruction, especially if there was overlying bulky deposits or flexion contractures. These deposits were most commonly found in the subcutaneous fat pads of the fingertips, along tendon and muscle groups, or within the carpal tunnel. DECT did not confirm MSU in our cohort with calcinosis. However, CT imaging was superior to plain radiographs in locating these deposits within the soft tissues and may be a useful tool to study SSc-calcinosis affecting the hands, particularly in the setting of progressive hand deformities.

Keywords Calcinosis · Systemic sclerosis

Introduction

Calcinosis, the deposition of calcified material in the skin and subcutaneous soft tissues, is frequently seen in patients with symptomatic systemic sclerosis (SSc). It has been reported that approximately 40 % of patients with limited SSc have calcinosis [1, 2]. Calcium hydroxyapatite [3] is reported to be the major constituent of SSc-calcinosis. Its pathogenesis is unknown, and currently, there is no effective cure or prevention. Deposits are commonly found in pressures areas of the elbows, knees, and hands. The hands may be involved in up to 70 % of those with SSc-calcinosis [3]. SSc-calcinosis can be asymptomatic or cause significant morbidity such as pain, intractable ulcers, and recurrent infections. SSc-calcinosis may be palpable on exam and/or diagnosed by imaging. Plain X-rays [4] are useful to confirm location of calcinosis and could be used to estimate the area of some of these deposits, whereas ultrasound [2, 3] and computed tomography (CT) [3, 5] are more helpful in showing the location of these deposits in the soft tissues and could be useful to quantitate the burden of calcinosis using volumetric measurements of many of these bulky and irregularly shaped deposits. Using standard CT with specialized software to permit dual-energy CT techniques, dual-energy computed tomography (DECT) is an advanced imaging modality useful for assessing monosodium urate (MSU) crystal deposition in gout [6–8]. The DECT utilizes two energy beams, usually a combination of 80- and 140-
kilovoltage peak (kVp) beams, and differences in attenuation enable differentiation between calcium hydroxyapatite and MSU crystals. Thus, DECT enables visualization of calcium deposits by analysis of the chemical content of scanned materials.

**Methods**

In this IRB-approved study, we performed DECT imaging with a 64-slice dual-source CT (Siemens Definition), using dual-energy application in patients with symptomatic SSc-calcinosis, to better characterize the location and radiographic details of SSc-calcinosis and exclude MSU. We also compared the DECT to plain X-ray radiographs in all 16 patients. All had known calcinosis confirmed by prior imaging or physical exam and met the American College of Rheumatology (ACR) criteria for definite SSc [9–11], either limited or diffuse cutaneous SSc. Hand symptoms included painful swelling surrounding the deposits, redness, or recurrent ulceration from draining calcinosis. Variables were precisely defined; standardized abstraction forms were used for data collection. The variables included gender, age, type of SSc, presence of overlap with other rheumatic diseases [12, 13] mean years of SSc, mean years of calcinosis, ischemic digital ulcer history, nailfold capillaroscopy (using portable DermLite DL100), calcinosis complications, calcinosis locations, and autoantibodies.

**Results**

The clinical, demographic, and serologic characteristics of our SSc patient cohort are summarized in Table 1. Sixteen SSc patients with symptomatic calcinosis of the hands confirmed by physical examination and/or prior imaging underwent DECT and plain X-ray imaging of the hands. Common calcinosis symptoms included pain at the site of deposits (88 %), soft tissue swelling (63 %) or recurrent infections (44 %) near the deposits. Their mean age was 59.3 (SD ± 14.6229, range 29–85) and mean disease duration (from onset of non-Raynaud symptoms) was 18.5 years (SD ± 10.0995, range 7–43 years). Nine of the 16 patients (56 %) had diffuse SSc. Five SSc patients had overlap disease: three with rheumatoid arthritis (RA), one had both RA and myopathy, and the other had SSc with myopathy. Most (12/16 or 75 %) developed calcinosis later in their disease course (mean duration of calcinosis 12.333 years (SD 10.0971, range 1–30)). A long history of ischemic digital ulcers (69 %) was common.

DECT confirmed calcinosis had the same density and color as the bone, and no MSU was found within or near any of these tumorous deposits. Common locations (see Table 1) included the subcutaneous fat pad of the fingertips, along tendon sheaths of the hands and wrists, within the carpal tunnel, and adjacent to muscle groups. These deposits ranged in size and shapes, some rounded, lobulated (popcorn-like), or in clusters and sheets following tendon and muscle groups (see Figs. 1, 2, and 3). Acro-osteolysis was quite common (94 %), and more than half of this cohort (9/16 patients) had clumps of calcinosis adjacent to their sites of bone destruction.

Plain X-ray imaging of the hands was sufficient to confirm and assess the size and distribution of calcinosis in most of our cohort, although in five subjects the DECT showed better

| Table 1 | Clinical and DECT characteristics in SSc-calcinosis cohort |
|---------|---------------------------------------------------------|
| Clinical characteristics | Number of patients (%) |
| Race | |
| Caucasian | 13 (81 %) |
| African-American | 3 (19 %) |
| SSc type | |
| Diffuse | 9 (56 %) |
| Limited | 7 (44 %) |
| SSc patients with overlap disease | |
| SSc with RA | 3 |
| SSc with RA and myopathy | 1 |
| SSc with myopathy | 1 |
| Mean age | 59.3 (SD ± 14.6229) |
| Mean years of SSc from non-Raynaud | 18.5 (SD ± 10.0995) |
| Mean years of calcinosis | 12.33 (SD ± 10.0971) |
| Ischemic digital ulcer history | 11 (69 %) |
| Digital pulp loss | 12 (75 %) |
| Abnormal nailfold capillaroscopy | 8 (50 %) |
| Calcinosis complications | |
| Pain | 14 (88 %) |
| Draining ulcer(s) | 11 (69 %) |
| Episodic swelling near deposits | 10 (63 %) |
| Infection | 7 (44 %) |
| Serology | |
| Antinuclear antibodies (ANA) | 14 (87 %) |
| Anti-topoisomerase (Scl 70) | 7 (44 %) |
| Anti-centromere (ACA) | 4 (25 %) |
| Nucleolar antibody | 4 (25 %) |
| Anti-ribonucleoprotein (RNP) | 3 (19 %) |
| RNA polymerase 3 | 2 (13 %) |
| Details seen on DECT scan | |
| Calcinosis locations | |
| Fingertip padding | 15 (94 %) |
| Hands | 13 (81 %) |
| Wrists | 8 (50 %) (5 in carpal tunnel) |
| Forearms | 5 (31 %) |
| Presence of acro-osteolysis | 15 (94 %) |
| Calcinosis near acro-osteolysis site | 9 (56 %) |
details due to significant flexion deformities or osteopenia in the presence of large and extensive calcinosis nearby. Figures 1, 2, and 3 compare representative DECT images with their plain radiographs of three subjects with significant hand deformities. Figures 1 and 2 were taken from two subjects with diffuse cutaneous scleroderma, both presented with increasingly painful flexion contractures of the hands. Their extensive calcinosis was confirmed incidentally by imaging. Figure 3 was a subject with limited cutaneous scleroderma and erosive arthritis, whose extensive joint destruction and bulky calcinosis were better demonstrated on DECT.

**Discussion**

We chose DECT to study SSc-calcinosis because of its capacity to show color produced by MSU deposition. If present, we expected MSU could be detected in the soft tissues, along
tendons or ligaments [7, 8], or perhaps as a component within the calcinosis. All but three of our subjects were older and had risk factors for gout, although never symptomatic. However, no MSU deposition was seen and the calcinosis appeared as white and dense as the bone on DECT.

Calcinosis has been reported to be more common in limited cutaneous SSc [1, 2], although most of our cohort with symptomatic SSc-calcinosis had diffuse SSc. Patients with more than 10 years of SSc-calcinosis typically had limited cutaneous SSc. These deposits were typically found along extensor surfaces of the hands, elbows, and knees, although rare locations such as the spine and anterior neck [3, 14] have been reported. Depending on location and size, calcinosis can affect quality of life and may be inflammatory in up to 20% of patients [3, 15].

Calcinosis in SSc-overlap with myopathy can be tumorous and found in similar locations in the soft tissues [3]. Both SSc patients with myopathy from our cohort had advanced SSc of more than 10 years duration. One patient had no knowledge of her calcinosis until X-rays were done to assess her worsening hand deformities (see Fig. 2). We found both SSc-myopathy patients had similar appearing calcinosis (limited to their hands) as the others without overlap disease.

Acro-osteolysis of the fingertips was common. Johnstone and others [15] reported more severe calcinosis and acro-osteolysis in patients with tissue damage due to severe digital ischemia and suggested that this may be a marker of more severe disease. Similarly, nailfold capillaroscopy has been helpful in predicting more severe scleroderma complications including digital ulcers from vasculopathy [16]. We found abnormal nailfold capillaroscopy in only half of our cohort.

Crystal composition of calcinosis in SSc patients has previously been identified as calcium hydroxyapatite [3], and the pathophysiology of how or why these are formed in SSc is unknown. Increased production of tumor necrosis factor α, interleukin (IL)-1, IL-6, and other pro-inflammatory cytokines has been reported in patients with SSc and systemic lupus erythematosus who have calcinosis [17, 18].

Calcinosis in our patients had a predilection for SQ fat, attached or near tendon sheaths and along muscle plains. Most (88%) patients reported pain (to palpation or with activity) at the site of their deposits, even if the area was not draining, which often affected their activities of daily living. Ten patients reported soft tissue swelling near the calcinosis site(s) just prior to spontaneous draining. We found that plain X-ray imaging of the hands was sufficient to view the size and distribution of calcinosis in most of our cohort, although in five subjects CT imaging showed better details due to extensive flexion deformities or osteopenia with nearby large calcinosis deposits. CT imaging found more destructive bone and joint disease in our four SSc patients with rheumatoid arthritis and calcinosis. Their calcinosis was otherwise similar in distribution, size, and extent as the rest of our cohort. Interesting, although their arthritis appeared well controlled clinically, all 4 SSc patients reported progressive and disabling hand deformities over the years. We found CT showed better 3-D details of calcinosis locations within the soft tissue structures and demonstrated more clearly how these could contribute to joint contractures or muscle atrophy. Thus, standard CT imaging.
should be considered in the evaluation of any SSc patient with progressive hand deformities, especially in the presence of bulky calcinosis, while DECT could be applied if MSU was suspected. Newer software is currently being developed to better differentiate between calcinosis and bone on standard CT, which would be very useful to quantify bulky calcinosis using volumetric measurements.

To our knowledge, we are the first group to use DECT to analyze calcinosis in a cohort of scleroderma patients. Our limitations include the small population of patients, five of whom also had overlap disease. However, their calcinosis did not appear any different or any more extensive than in those without overlap disease, and further studies are needed to determine the differences in pathophysiology between those with and without overlap disease.

Conclusion

Although no MSU crystals were confirmed by DECT in our cohort, CT imaging is a more useful tool to study patients with bulky SSc-calcinosis affecting the hands.

Disclosures None.

Authors’ contributions Hsu and Schlesinger were responsible for the study conception and design. Hsu and Bramwit were responsible for the acquisition of data. Hsu and Schlesinger were responsible for the analysis and interpretation of data. All authors were involved in drafting or revising the manuscript critically for important intellectual content, and all authors approved the final version to be published. Dr. Hsu had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Source of support This study was supported by the Rutgers-RWJ Scleroderma Research Fund.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anti-centromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27(2):125–131

2. Elhai M, Guerini H, Bazeli R, Avouac J, Freire V, Drape JL et al (2012) Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res 64(8):1244–1249

3. Gutierrez A, Wetter DA (2012) Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 25:195–206

4. Chung L, Valenzuela A, Fiorentino D, Stevens K, Li S, Harris J et al (2015) Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Arthritis Care Res 67(3):425–430

5. Freire V, Becce F, Feidy A, Guerini H, Campagna R, Allanore Y et al (2013) MDCT imaging of calcinosis in systemic sclerosis. Clin Radiol 68(3):302–309

6. Girish G, Melville DM, Kaeley GS, Brandon CJ, Goyal JR, Jacobson JA et al (2013) Imaging appearances in gout. Arthritis. doi:10.1155/2013/673401

7. Deng K, Sun C, Liu C, Ma R (2009) Initial experience with visualizing hand and foot tendons by dual-energy computed tomography. Clin Imaging 33(5):384–389

8. Choi K, Al-Arfaj AM, Eftekari A, Munk PL, Shojaian K, Reid G et al (2009) Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 68(10):1609–1612

9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

11. Hoogen FVD, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755, Arthritis Rheum 2013; 65(11):2737–57

12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Bingham NS, Burmester GR, Bykerk VP, Cohen MD et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

13. Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 28(4):723–741

14. Ogawa T, Ogura T, Ogawa K, Hirata A, Hayashi N, Izumi Y et al (2009) Paraspinal and intraspinal calcinosis: frequent complications in patients with systemic sclerosis. Ann Rheum Dis 68:1655–1656

15. Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL (2012) Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. Rheumatology 51(12):2234–2238

16. Ghizzoni C, Sebastiani M, Manfredi A, Campomori F, Colaci M, Giuglioli D et al (2015) Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: clinical and prognostic implications. Microvasc Res 99:92–95

17. Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A et al (2006) Radiologic hand involvement in systemic sclerosis. Ann Rheum Dis 65:1088–1092

18. Chander S, Gordon P (2012) Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol 24(2):158–164